Antifungal player F2G banks $60M, eyes IPO in leadup to a PhIII trial
On Monday, as Circassia’s (LSE: $CIR) shares shriveled in value in the wake of a Phase III failure, a pair of UK biotechs raised …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
